Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Whooping cough and walking pneumonia have been added to this group of infections this year as the Centers for Disease Control ...

New research led by investigators at Mass General Brigham suggests that vaccination earlier in that timeframe, closer to 32 weeks, could provide the best protection for newborns against RSV. The ...

Respiratory syncytial virus and influenza activity are on the rise in parts of the country, particularly among young children, according to the CDC's latest respiratory virus updates. Overall, the ...

This year's headlines on respiratory syncytial virus (RSV) focused largely on the relatively new vaccines -- including a new ...

Researchers found that vaccine effectiveness was 80% and 81% against RSV-associated hospitalizations and against RSV-associated critical illness among 28,271 hospitalizations for RSV-like illness ...

Sure, I’m neurotic, but it wasn’t just that: Infecting a newborn with RSV is a very real risk when they live with a Petri ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Weekly COVID-19 case numbers reported by the Montana Department of Public Health and Human Services continue to drop.There ...